Titlebook: Systems Biology in Biotech & Pharma; A Changing Paradigm Aleš Prokop,Seth Michelson Book 2012 The Author(s) 2012 Biochemical Networks.Compu

易怒

,Integrative Systems Biology II—Molecular Biology: Phase 2 Lead Discovery and , Screening,em, ChIP-on-chip is used to investigate interactions between proteins and DNA in vivo. Chemogenomics, morphogenics and synthetic biology are only in the early stages of development, but may contribute to target identification. A key SB tool, the reconstruction of biological networks, represents an e

以烟熏消毒

尊敬

,Development: In Vivo Pharmacology—Systems Biology in Health and Disease II,y, we cover RNA interference in this chapter even though it is largely an in vitro method for characterizing the dynamics of cell physiology. And though in silico pharmacology is only in a rudimentary state, it is vitally important for clinical model based drug design (MBDD) development (see Chap. 1

使人烦燥

,Development: Multiscale CSB—Simulation Tools,junction with multiscale modeling tools which have the ability to handle many orders of magnitude in both length and timescale. Several new R&D paradigms, based on CSB, are proposed, while some are already in the research stage. This effort will lead to virtual organ/disease models, emerging as impo

insomnia

Development: Drug Formulation and Delivery,o improved modalities. The whole landscape will change very soon and it will have a key role to play in replacing existing drugs with expiring patents. Nanoscale delivery methods are in rapid development, and will allow for efficient cell internalization and enhanced efficacy.

试验

代替

Cultivate

Discovery: Use of Systems Biology for Identifying Targets,lecular probes (compounds) that will enable the investigation of fundamental biological function at molecular, cellular and whole organism levels. Such screening usually occurs at the earlier stages of drug discovery.

confederacy

Ardent